123 related articles for article (PubMed ID: 37946551)
1. Efficacy and safety of TM5614 in combination with paclitaxel in the treatment of paclitaxel-resistant cutaneous angiosarcoma: Phase II study protocol.
Fujimura T; Yoshino K; Nakamura M; Kato H; Ito T; Maekawa T; Fujisawa Y; Matsushita S; Amagai R; Yamazaki E; Takahashi M; Tamabuchi E; Hashimoto A; Kambayashi Y; Yamazaki N; Miyata T; Asano Y
Exp Dermatol; 2024 Jan; 33(1):e14976. PubMed ID: 37946551
[TBL] [Abstract][Full Text] [Related]
2. Clinical benefit of switching from paclitaxel to docetaxel or vice versa in cutaneous angiosarcoma patients resistant to first taxane chemotherapy.
Yonekura S; Endo Y; Fujii H; Ishikawa M; Egawa G; Kabashima K
J Dermatol; 2023 Nov; 50(11):1493-1496. PubMed ID: 37400887
[TBL] [Abstract][Full Text] [Related]
3. Treatment for taxane-resistant cutaneous angiosarcoma: A multicenter study of 50 Japanese cases.
Fujimura T; Maekawa T; Kato H; Ito T; Matsushita S; Yoshino K; Fujisawa Y; Ishizuki S; Segawa K; Yamamoto J; Hashimoto A; Kambayashi Y; Asano Y
J Dermatol; 2023 Jul; 50(7):912-916. PubMed ID: 36938650
[TBL] [Abstract][Full Text] [Related]
4. A single-arm confirmatory trial of pazopanib in patients with paclitaxel-pretreated primary cutaneous angiosarcoma: Japan Clinical Oncology Group study (JCOG1605, JCOG-PCAS protocol).
Oashi K; Shibata T; Namikawa K; Takahashi A; Yokota K; Nakano E; Teramoto Y; Tsutsumida A; Maeda T; Yamazaki N;
BMC Cancer; 2020 Jul; 20(1):652. PubMed ID: 32660439
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of a combination of paclitaxel and radiation therapy against cutaneous angiosarcoma: A single-institution retrospective study of 21 cases.
Seo T; Kitamura S; Yanagi T; Ujiie H
J Dermatol; 2022 Mar; 49(3):383-386. PubMed ID: 34881462
[TBL] [Abstract][Full Text] [Related]
6. Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy-the P-SELECT trial (WJOG10617G)-a randomised phase II trial by the West Japan Oncology Group.
Hirata K; Hamamoto Y; Ando M; Imamura CK; Yoshimura K; Yamazaki K; Hironaka S; Muro K
BMC Cancer; 2020 Jun; 20(1):548. PubMed ID: 32532230
[TBL] [Abstract][Full Text] [Related]
7. Intraperitoneal paclitaxel combined with FOLFOX/CAPOX plus bevacizumab for colorectal cancer with peritoneal carcinomatosis (the iPac-02 trial): study protocol of a single arm, multicenter, phase 2 study.
Murono K; Yokoyama Y; Nozawa H; Sasaki K; Emoto S; Matsuzaki H; Kashiwabara K; Ishigami H; Gohda Y; Yamaguchi H; Kitayama J; Ishihara S
Int J Colorectal Dis; 2023 Jun; 38(1):173. PubMed ID: 37340243
[TBL] [Abstract][Full Text] [Related]
8. Plasminogen activating inhibitor-1 promotes angiogenesis in cutaneous angiosarcomas.
Ohuchi K; Amagai R; Ikawa T; Muto Y; Roh Y; Endo J; Maekawa T; Kambayashi Y; Asano Y; Fujimura T
Exp Dermatol; 2023 Jan; 32(1):50-59. PubMed ID: 36168721
[TBL] [Abstract][Full Text] [Related]
9. Anti-PD-1 antibody therapy for epithelial skin malignancies: An investigator-initiated, open-label, single-arm, multicenter, phase II clinical trial (NMSC-PD1 Study).
Ishii M; Hirai I; Tanese K; Fusumae T; Nakamura Y; Fukuda K; Uchi H; Kabashima K; Otsuka A; Yokota K; Yamazaki N; Namikawa K; Fujimura T; Takenouchi T; Yamamoto Y; Nishiguchi M; Sato Y; Amagai M; Funakoshi T
Medicine (Baltimore); 2020 Oct; 99(44):e22913. PubMed ID: 33126349
[TBL] [Abstract][Full Text] [Related]
10. Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial.
Yardley DA; Brufsky A; Coleman RE; Conte PF; Cortes J; Glück S; Nabholtz JM; O'Shaughnessy J; Beck RM; Ko A; Renschler MF; Barton D; Harbeck N
Trials; 2015 Dec; 16():575. PubMed ID: 26673577
[TBL] [Abstract][Full Text] [Related]
11. Sintilimab plus nab-paclitaxel as second-line treatment for advanced biliary tract cancer: study protocol for an investigator-initiated phase 2 trial (NapaSinti trial).
Zhou N; Li X; Yang Y; Tan S; Zhang S; Huang Q; Gou H
BMC Cancer; 2023 Aug; 23(1):729. PubMed ID: 37550655
[TBL] [Abstract][Full Text] [Related]
12. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
13. Combination chemotherapy with S-1 and docetaxel for cutaneous angiosarcoma resistant to paclitaxel.
Kajihara I; Kanemaru H; Miyake T; Aoi J; Masuguchi S; Fukushima S; Jinnin M; Ihn H
Drug Discov Ther; 2015 Feb; 9(1):75-7. PubMed ID: 25788055
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of MIKE-1 in patients with advanced pancreatic cancer: a study protocol for an open-label phase I/II investigator-initiated clinical trial based on a drug repositioning approach that reprograms the tumour stroma.
Mizutani Y; Iida T; Ohno E; Ishikawa T; Kinoshita F; Kuwatsuka Y; Imai M; Shimizu S; Tsuruta T; Enomoto A; Kawashima H; Fujishiro M
BMC Cancer; 2022 Feb; 22(1):205. PubMed ID: 35209871
[TBL] [Abstract][Full Text] [Related]
15. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
[TBL] [Abstract][Full Text] [Related]
16. A randomized double-blind placebo-controlled trial of an inhibitor of plasminogen activator inhibitor-1 (TM5614) in mild to moderate COVID-19.
Hirai T; Asano K; Ito I; Miyazaki Y; Sugiura H; Agirbasli M; Kobayashi S; Kobayashi M; Shimada D; Natsume I; Kawasaki T; Ohba T; Tajiri S; Sakamaki F; Mineshita M; Takihara T; Sekiya K; Tomii K; Tomioka H; Kita H; Nishizaka Y; Fukui M; Miyata T; Harigae H
Sci Rep; 2024 Jan; 14(1):165. PubMed ID: 38168544
[TBL] [Abstract][Full Text] [Related]
17. Ramucirumab plus irinotecan / leucovorin / 5-FU versus ramucirumab plus paclitaxel in patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed one prior line of palliative chemotherapy: the phase II/III RAMIRIS study (AIO-STO-0415).
Lorenzen S; Schwarz A; Pauligk C; Goekkurt E; Stocker G; Knorrenschild JR; Illerhaus G; Dechow T; Moehler M; Moulin JC; Pink D; Stahl M; Schaaf M; Goetze TO; Al-Batran SE
BMC Cancer; 2023 Jun; 23(1):561. PubMed ID: 37337155
[TBL] [Abstract][Full Text] [Related]
18. Nab-paclitaxel maintenance therapy following carboplatin + nab-paclitaxel combination therapy in chemotherapy naïve patients with advanced non-small cell lung cancer: multicenter, open-label, single-arm phase II trial.
Nakao A; Uchino J; Igata F; On R; Ikeda T; Yatsugi H; Hirano R; Sasaki T; Tanimura K; Imabayashi T; Tamiya N; Kaneko Y; Yamada T; Nagata N; Watanabe K; Kishimoto J; Takayama K; Fujita M
Invest New Drugs; 2018 Oct; 36(5):903-910. PubMed ID: 29846848
[TBL] [Abstract][Full Text] [Related]
19. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
20. Study protocol for an open-label, single-arm, phase Ib/II study of combination of toripalimab, nab-paclitaxel, and gemcitabine as the first-line treatment for patients with unresectable pancreatic ductal adenocarcinoma.
Shui L; Cheng K; Li X; Shui P; Zhou X; Li J; Yi C; Cao D
BMC Cancer; 2020 Jul; 20(1):636. PubMed ID: 32646394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
